The ability of positive transcription elongation factor b to transactivate human immunodeficiency virus transcription depends on a functional kinase domain, cyclin T1, and Tat

被引:150
作者
Fujinaga, K
Cujec, TP
Peng, JM
Garriga, J
Price, DH
Graña, X
Peterlin, BM [1 ]
机构
[1] Univ Calif San Francisco, Howard Hughes Med Inst, Dept Med, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Howard Hughes Med Inst, Dept Microbiol, San Francisco, CA 94143 USA
[3] Univ Calif San Francisco, Howard Hughes Med Inst, Dept Immunol, San Francisco, CA 94143 USA
[4] Univ Iowa, Coll Med, Dept Biochem, Iowa City, IA 52242 USA
[5] Temple Univ, Hlth Sci Ctr, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA
[6] Temple Univ, Hlth Sci Ctr, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA
关键词
D O I
10.1128/JVI.72.9.7154-7159.1998
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
By binding to the transactivation response element (TAR) RNA, the transcriptional transactivator (Tat) from the human immunodeficiency virus increases rates of elongation rather than initiation of viral transcription. Two cyclin dependent serine/threonine kinases, CDK7 and CDK9, which phosphorylate the C-terminal domain of RNA polymerase II, have been implicated in Tat transactivation in vivo and in vitro. In this report, we demonstrate that CDK9, which is the kinase component of the positive transcription elongation factor b (P-TEFb) complex, can activate viral transcription when tethered to the heterologous Rev response element RNA via the regulator of expression of virion proteins (Rev). The kinase activity of CDK9 and cyclin T1 is essential for these effects. Moreover, P-TEFb binds to TAR only in the presence of Tat. We conclude that Tat-P-TEFb complexes bind to TAR, where CDK9 modifies RNA polymerase II for the efficient copying of the viral genome.
引用
收藏
页码:7154 / 7159
页数:6
相关论文
共 38 条
  • [1] REQUIREMENT FOR TFIIH KINASE-ACTIVITY IN TRANSCRIPTION BY RNA-POLYMERASE-II
    AKOULITCHEV, S
    MAKELA, TP
    WEINBERG, RA
    REINBERG, D
    [J]. NATURE, 1995, 377 (6549) : 557 - 560
  • [2] THE RNA-POLYMERASE-II ELONGATION COMPLEX
    ASO, T
    CONAWAY, JW
    CONAWAY, RC
    [J]. FASEB JOURNAL, 1995, 9 (14) : 1419 - 1428
  • [3] REGULATION OF TRANSCRIPTIONAL ELONGATION BY RNA-POLYMERASE-II
    BENTLEY, DL
    [J]. CURRENT OPINION IN GENETICS & DEVELOPMENT, 1995, 5 (02) : 210 - 216
  • [4] BULLRICH F, 1995, CANCER RES, V55, P1199
  • [5] Caputo A, 1996, GENE THER, V3, P235
  • [6] INHIBITION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 TAT ACTIVITY BY COEXPRESSION OF HETEROLOGOUS TRANS ACTIVATORS
    CARROLL, R
    PETERLIN, BM
    DERSE, D
    [J]. JOURNAL OF VIROLOGY, 1992, 66 (04) : 2000 - 2007
  • [7] The HIV transactivator TAT binds to the CDK-activating kinase and activates the phosphorylation of the carboxy-terminal domain of RNA polymerase II
    Cujec, TP
    Okamoto, H
    Fujinaga, K
    Meyer, J
    Chamberlin, H
    Morgan, DO
    Peterlin, BM
    [J]. GENES & DEVELOPMENT, 1997, 11 (20) : 2645 - 2657
  • [8] The human immunodeficiency virus transactivator Tat interacts with the RNA polymerase II holoenzyme
    Cujec, TP
    Cho, H
    Maldonado, E
    Meyer, J
    Reinberg, D
    Peterlin, BM
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 1997, 17 (04) : 1817 - 1823
  • [9] ACCURATE TRANSCRIPTION INITIATION BY RNA POLYMERASE-II IN A SOLUBLE EXTRACT FROM ISOLATED MAMMALIAN NUCLEI
    DIGNAM, JD
    LEBOVITZ, RM
    ROEDER, RG
    [J]. NUCLEIC ACIDS RESEARCH, 1983, 11 (05) : 1475 - 1489
  • [10] PROGRESS IN ANTI-HIV STRUCTURE-BASED DRUG DESIGN
    GAIT, MJ
    KARN, J
    [J]. TRENDS IN BIOTECHNOLOGY, 1995, 13 (10) : 430 - 438